Natco Pharma Launches First Generic Hep C Med in India

Source: Business Standard

Jan 02, 2017

Hyderabad-based Natco Pharma has launched the first generic version of Gilead's Sofosbuvir in Nepal.

Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, under the brand name Epclusa.

Natco will market Sofosbuvir under the name Velpanat as a single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Read the Business Standard coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments